logo-loader
viewScancell Holdings PLC

Scancell highlights significantly strengthened cash position

For the six months ended October 31, the developer of immunotherapies said it had ended the period with £25.7mln in cash compared to £3.6mln in April last year, while post-period another £20.5mln had been raised

Scancell Holdings PLC - Scancell highlights significantly strengthened cash position

Scancell Holdings PLC (LON:SCLP) said it has “significantly strengthened” its cash position which it noted will accelerate its pipeline of novel therapies for cancer and advance its vaccine candidate for coronavirus (COVID-19).

In its results for the six months ended October 31, 2020, the developer of immunotherapies said it ended the period with £25.7mln in cash compared to £3.6mln in April last year, while post-period another £20.5mln had been raised from the issue of convertible loan notes and an open offer to shareholders.

READ: Scancell Holdings chooses candidate for coronavirus vaccine

In the figures, the pre-revenue company reported a pre-tax loss for the period of £4.3mln compared to £3.08mln in the prior year.

Looking ahead, Scancell said the additional funding is “transformational” and will enable it to move forward on a number of fronts including moving its COVID-19 vaccine candidate through planned clinical trials, accelerating and broadening its development pipeline of novel therapies, expanding its resources and capabilities in development and clinical operations and broadening its intellectual property portfolio.

"We are pleased to report a period of strong operational and financial progress for Scancell, having transformed the group's cash balance through two transactions with the support of our shareholders. 2021 is set to be an exciting year for the business”, Scancell chief executive Cliff Holloway said in a statement.

“We continue to work towards developing an effective and differentiated vaccine against COVID-19, potentially active against new variants of the SARS-CoV-2 virus, whilst also making progress with our Moditope, ImmunoBody and AvidiMab platforms. We would like to thank our shareholders for their continued support over the past 6 months and look forward to utilising the proceeds raised to propel the business forward", he added.

Quick facts: Scancell Holdings PLC

Price: 21 GBX

LSE:SCLP
Market: LSE
Market Cap: £171.2 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Scancell Holdings highlights 'most transformative period Scancell has ever...

Scancell Holdings PLC's (LON:SCLP) Cliff Holloway talks to Proactive London about the six month period ending ended October 31, 2020, described by Holloway as the 'most transformative period Scancell has ever experienced'. He highlights their strengthened cash position, 'which has allowed us...

on 1/2/21

2 min read